Hoerter Steven L. 4

What Happened

• Steven L. Hoerter, a director of C4 Therapeutics, was granted a derivative equity award for 62,000 shares on June 24, 2026. The Form 4 reports an acquisition price of $0.00 (reported value $0), indicating a grant of rights rather than a cash purchase.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (filed within the usual two-business-day window).
• Transaction type/code: A (Grant/Award — derivative securities).
• Shares/rights granted: 62,000 (acquisition price reported as $0.00; no cash exchanged).
• Shares owned after transaction: Not disclosed in the provided filing details.
• Footnote: Award vests in full upon the earlier of (i) June 24, 2027 or (ii) the next annual meeting of stockholders, subject to continued service as a Board member.
• No indication of sale, open‑market purchase, or immediate exercise; no tax-withholding or 10b5-1 plan noted.

Context

• This is a compensation-style award to a director (routine corporate practice) rather than an insider purchase or sale signaling a trading decision. The award is a derivative right and will only convert to exercisable/owned shares if and when it vests per the footnote conditions.